Anti-TIM-3
Showing 26 - 50 of >10,000
Glanzmann Thrombasthenia Trial in France (Antibodies screening)
Active, not recruiting
- Glanzmann Thrombasthenia
- Antibodies screening
-
Bordeaux, France
- +8 more
Jul 5, 2022
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/
Not yet recruiting
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- SHR-A1811
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- (no location specified)
Nov 6, 2023
Acute Myeloid Leukemia Trial in Wuhan (Fludarabine + Cyclophosphamide + TAA05 Cell Injection)
Recruiting
- Acute Myeloid Leukemia
- Fludarabine + Cyclophosphamide + TAA05 Cell Injection
-
Wuhan, Hubei, ChinaWuhan Union Hospital
Jun 29, 2022
Gingivitis Trial in Baghdad (Capitano zenzero toothpaste, Colgate total toothpaste)
Completed
- Gingivitis
- Capitano zenzero toothpaste
- Colgate total toothpaste
-
Baghdad, IraqZainab
May 11, 2023
Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)
Not yet recruiting
- Relapsed Refractory Multiple Myeloma
- REGN5458
- +3 more
- (no location specified)
Feb 6, 2023
Inflammation, Spinal Cord Injuries, Multiple Sclerosis Trial in St. Catharines (Mad Dog Dietary Consultation)
Completed
- Inflammation
- +4 more
- Mad Dog Dietary Consultation
-
St. Catharines, Ontario, CanadaBrock University
May 29, 2023
Psoriasis Trial in Shanghai (608 Q2W, 608 Q4W, Placebo)
Not yet recruiting
- Psoriasis
- 608 Q2W
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Huanshan Hospital Fudan University
Sep 8, 2022
Hidradenitis Suppurativa Trial (Upadacitinib, Placebo)
Not yet recruiting
- Hidradenitis Suppurativa
- Upadacitinib
- Placebo
- (no location specified)
May 26, 2023
Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Nivolumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 31, 2022
Colorectal Cancer, Cancer of Pancreas, Pancreatic Tumor Trial in Detroit (FOLFOX6, EGFRBi armed ATC Infusions)
Completed
- Colorectal Cancer
- +7 more
- FOLFOX6
- EGFRBi armed ATC Infusions
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 30, 2022
B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)
Not yet recruiting
- B-cell Non-Hodgkins Lymphoma (B-NHL)
- (no location specified)
Jan 5, 2023
Advanced Malignant Tumors(Stage IA-IB) Trial in Beijing (AK129 IV infusion)
Not yet recruiting
- Advanced Malignant Tumors(Stage IA-IB)
- AK129 IV infusion
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Science
Jan 17, 2023
Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed
Not yet recruiting
- Pediatric Cancer
- +11 more
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
-
Milwaukee, WisconsinChildren's Wisconsin
Sep 14, 2022
Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS) Trial in Marseille (blood samples)
Completed
- Axial Spondyloarthritis (axSpA)
- Ankylosing Spondylitis (AS)
- blood samples
-
Marseille, FranceAssistance Publique Hopitaux de Marseille
Aug 31, 2022
Metastatic Breast Cancer Trial in Charlottesville (HER2 BATs with Pembrolizumab)
Recruiting
- Metastatic Breast Cancer
- HER2 BATs with Pembrolizumab
-
Charlottesville, VirginiaAshley Donihee
Jan 18, 2023
Spinal Cord Injuries, Multiple Sclerosis, Diet, Healthy Trial in St. Catharines (Mad Dog cooking class series)
Not yet recruiting
- Spinal Cord Injuries
- +5 more
- Mad Dog cooking class series
-
St. Catharines, Ontario, CanadaBrock University
Jul 6, 2023
Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (biological, procedure, drug)
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Atezolizumab
- +5 more
- (no location specified)
Feb 4, 2023
Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)
Recruiting
- Follicular Lymphoma (FL)
- Odronextamab
- +5 more
-
Noblesville, IndianaInvestigative Clinical Research of Indiana
Oct 18, 2023
NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)
Terminated
- Non-small Cell Lung Cancer
- REGN2810/ipi
- +2 more
-
Saint Petersburg, Florida
- +2 more
Oct 22, 2022